Weather 
The thought of pumping her breasts full of a dead person’s fat didn’t give Nicole goosebumps.
Neither did she flinch at the $10,000 cost of AlloClae, a trendy non-surgical route to breast enhancement that uses “ethically sourced” cadaver filler. The slight, 40-something Californian, who spoke to The Post on the condition that her privacy be protected, was eager for the fast, knife-free silhouette of her dreams.
She’d previously spent almost $20,000 on two unsuccessful fat-grafting procedures, transferring what little chub she had into her barely-there bust, hoping to go up one cup size.
Instead, she got breasts full of rock-like, inoperable bumps and oil cysts, causing her chest to feel like “the surface of the moon.”
“I lay down in bed each night and touch the lumps, the pebbles,” said Nicole of the off-the-shelf fat that’s turned her life into a nightmare.
Nicole isn’t alone in her skepticism of the trendy treatment. AlloClae, billed as the first use of structural adipose tissue from dead donors for aesthetic body procedures, centers a legal dispute between the New York State Department of Health and its manufacturer, medical technology imprint, Tiger Aesthetics.
The company recently sued the DOH, alleging the “unlawful and arbitrary” denial of distribution licenses. String back, the DOH, which regulates all tissue use and banking across the state, accused Tiger Aesthetics of “smuggling” AlloClae into New York via unsavory means, per court documents. The case is ongoing.
Nicole’s experience with the injectable is entirely unrelated to the lawsuit. But she is in favor of any extensive probe into the suspect shot that’s likely left her permanently damaged.
“When I first saw a plastic surgeon’s Instagram post about AlloClae, it sounded like a miracle,” she said. “Now, I regret ever getting it.”
The chorus of remorse is growing online, as buyers bemoan their experiences.
“Money not well spent,” one anonymous social media user warned — saying the product doesn’t last.
“For me, [it wasn’t] worth the money or trouble,” groaned another, claiming she’s developed recurring cysts in both breasts after paying roughly $14,000 for AlloClae. “It was a complete and utter bust (pun intended).”
When asked about the complaints, a spokesperson for Tiger Aesthetics confirmed to The Post that the product is not “risk-free.”
“There are risks associated with any procedure or treatment, including autologous fat transfer, and AlloClae should not be considered risk-free simply because it is allogeneic,” said the representative — adding that Tiger “cannot responsibly comment on any individual report” without understanding the full clinical picture of the individual.
“Any new breast lump or cyst should be evaluated by the treating physician using standard clinical judgment, which may include physical examination and appropriate imaging,” they recommended.
Examinations and imaging are now Nicole’s new normal.
The trouble began when she purchased three boxes of AlloClae from her plastic surgeon, whose name she asked to withhold, in November.
Unfussy upgrades are a supposed perk of AlloClae, widely hailed by medical professionals and influencers alike since its 2024 US debut.
Nicole was ready to transform her chest in 30 minutes or less. But the hopeful wasn’t prepared for the agony she endured during the minimally invasive ordeal.
“It was excruciatingly painful and disorienting. I felt like fainting,” she recalled of her experience, even with a numbing agent in each nipple. “Afterwards my breasts were swollen and lumpy. I figured they’d eventually [heal].”
But by February, the West Coaster’s hopes of sporting sexier bras and swimsuits this summer were dashed.
“Once the swelling went down, the little volume I’d gained … went away,” she said. “I had huge oil cysts and fat necrosis lumps forming in my chest.”
Her healthcare providers didn’t even know how to help.
“I got an ultrasound in March and a breast MRI in May,” said Nicole. “The radiologists called [the masses] oversized granulomas, which partially obscure the evaluation and limit their ability to determine my noncancerous lumps from any new, [potentially malignant] lumps that may develop.”
“When I get [medical] scans, some doctors don’t even know what AlloClae is,” she lamented. “It’s hard for people, even medical professionals, to relate.”
Tommaso Adonna, a board-certified plastic surgeon and the president of the New York Plastic Surgical Group, told The Post fat necrosis, or the death of fatty tissue, can occur when there’s insufficient blood flow to the area where the new fat — be it a patient’s own supply or donor-derived — is being introduced.
“There’s [often] not enough vascularity to create healthy fat within this adipose matrix, which is almost like a scaffold outside of a building,” said Addona, an admitted AlloClae skeptic. “Blood flow into the matrix doesn’t always work.”
The cosmetic breast specialist assures that necrosis and oil cyst masses, from either fat-grafting or AlloClae, are noncancerous. But he concedes that the growths can be troublesome to patients.
“Having bumps in your breast may generate more imaging with radiologists, whether it be ultrasound, mammograms, MRIs and potential biopsies,” said Addona.
Until he sees some “very favorable literature” on the treatment in breast applications, the expert is “holding off” on offering it to patients.
But not all plastic surgeons and medical spas are taking the wait-and-see approach — instead, they’re eagerly rushing to meet demand.
But the New York State Department of Health is curbing the haste. It has repeatedly rejected Tiger Aesthetics’ application to process, store and distribute the product in New York, stating, “it is unclear that AlloClae is in compliance with FDA requirements,” per court documents.
Joseph Giovannetti, the Director of the Bureau of Investigations within the Division of Legal Affairs for the Department of Health, filed docs in June, accusing Tiger of masterminding “a scheme to circumvent DOH’s prohibition against distributing AlloClae” by shipping the product to residences and a business in Connecticut and New Jersey, where it would then be “smuggled” into New York.
The filings included purchase invoices between Tiger and Dr. Adam Schaffner, a triple-board certified plastic surgeon on Fifth Avenue. The paperwork, according to the suit, indicated shipments to his employees in Marlborough, Connecticut, and Tinton Falls, New Jersey.
At least one of Schaffner’s invoices listed Sanaz Sarahian, a board-certified aesthetic provider at Sunny Medical Aesthetic in Wyckoff, NJ, as a recipient of his AlloClae inventory.
Sarahian told DOH investigators that the packages were delivered to her practice, then picked up by an Uber courier, who, to her knowledge, transported the goods into Gotham, per the filing.
Sarahian did not immediately respond to The Post’s request for a comment.
Additional FedEx shipping information, subpoenaed by the DOH, revealed dozens of boxes containing AlloClae — which should be stored at an ambient temperature of 59 to 86 degrees Fahrenheit until ready for use — stacked outside of the home of Robert McGee, a New Jersey plastic surgery nurse, per court records.
The DOH ultimately determined that Tiger had shipped over 330 boxes of AlloClae, purchased by approximately 40 New York State-based plastic surgeons and medical spas — including Schaffner’s midtown practice — to McGee’s home between September 2025 and April 2026, according to Giovannetti’s submission.
McGee, per the docs, admitted to receiving cartons of AlloClae and hauling them into NYC in his pick-up truck. He also did not respond to The Post’s request for a comment.
Representatives for Schaffner told The Post, “Dr. Adam Schaffner and the Plastic Surgery Institute of New York are complying with published New York State Department of Health guidance regarding Tissue Transplantation Facilities,” adding a copy of the DOH’s guidance for licensure.
“As this is an ongoing matter, we are not permitted to provide any further comment on this matter at this time,” said the rep.
Meanwhile, Tiger argues that the state’s stymying has “disrupted patient care, lost physician trust, damaged market reputation, [and] loss of limbs and life,” their petition reads.
Tiger’s representative told The Post it’s in “active and constructive settlement talks with the DOH and [is] confident we will get to a mutually agreeable solution.”
The company also notes that AlloClae “is regulated under federal law by the US Food & Drug Administration,” and “is legal and permitted for sale across all US states.”
“The DOH has stated that a tissue banking license in New York State is not necessary for terminally sterilized finished products, which AlloClae is, and which Tiger has proven with various studies submitted to the DOH in the last two years,” added the spokesperson.
The outcome of the legal proceedings, which are solely specific to New York, won’t immediately impact users like Nicole in other states. But she hopes the case inspires more “research and regulatory scrutiny” around the controversial commodity.
“I was so caught up in the hype of AlloClae that I became one of the first people to get it in my breasts without much proof of its long-term effects,” said Nicole, whose necrosis and oil cysts are no longer visible, but remain palpable. “It weighs on me everyday.”
“I’ll never be 100% lump free,” she said, claiming she’s been advised that removing the tiny nuisances would render her chest riddled with dents. “They may shrink or soften, but they’re here for life.”
